Previous close | 20.40 |
Open | 19.90 |
Bid | 0.00 x 80000 |
Ask | 0.00 x 80000 |
Day's range | 19.90 - 19.90 |
52-week range | 10.40 - 22.00 |
Volume | |
Avg. volume | 0 |
Market cap | 1.715B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript May 8, 2024 Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and welcome to the Syndax First Quarter 2024 Earnings Conference Call. Today’s call is […]
Insights into SNDX's robust pipeline progress, financial health, and strategic plans for upcoming drug launches.
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.